CHRS: Coherus BioSciences, Inc. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 89.01
Enterprise Value ($M) 255.83
Book Value ($M) -87.97
Book Value / Share -0.76
Price / Book -1.01
NCAV ($M) -177.47
NCAV / Share -1.54
Price / NCAV -0.50

Profitability (mra)
Return on Invested Capital (ROIC) -0.00
Return on Assets (ROA) -0.00
Return on Equity (ROE) n/a

Liquidity (mrq)
Quick Ratio 1.51
Current Ratio 2.11

Balance Sheet (mrq) ($M)
Current Assets 415.50
Assets 505.00
Liabilities 592.97
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
4 days ago 13G Rubric Capital Management LP 9.03
07-23 13G/A Temasek Holdings (Private) Ltd 4.80 -10.99
02-14 13G/A Alliancebernstein L.p. 0.10 -97.49
02-14 13G/A Citadel Advisors Llc 1.80
02-13 13G/A Vanguard Group Inc 9.30 78.09
01-24 13G/A BlackRock, Inc. 10.80 3.68
01-22 13G/A State Street Corp 1.85 -69.58
12-07 13G/A Jpmorgan Chase & Co 0.10 -97.80

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-06 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q
2024-08-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q
2024-05-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q
2024-03-15 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-11-15 1,148,432 2,895,627 39.66
2024-11-14 1,106,385 2,315,832 47.77
2024-11-13 582,192 2,269,976 25.65
2024-11-12 1,109,955 3,277,822 33.86
2024-11-11 716,217 2,462,182 29.09

(click for more detail)

Similar Companies
CADL – Candel Therapeutics, Inc. CARM – Carisma Therapeutics, Inc.
CGTX – Cognition Therapeutics, Inc. CLSD – Clearside Biomedical, Inc.
CLYM – Climb Bio, Inc.


Financial data and stock pages provided by
Fintel.io